We operate 8 API manufacturing sites (6 sites in India, one site in UK and one site in Mexico). Each of these sites has a dedicated purpose associated with capacity, capability, desired market and appropriate regulatory status.
Our capability footprint:
CTO-I is our dedicated state-of-the-art manufacturing plant where we produce Highly Potent APIs (HPAPIs). It is audited by the US FDA, MHRA, KFDA, and TGA. The warehouse is specially designed for handling highly potent raw materials in both solid and liquid forms. The facility has different dedicated modules for large and small batch sizes, with all prerequisites to handle high potent molecules. Our reactor capacity ranges from 5 L to 1000 L.
The facility also has special unit operations across all the modules ranging from material removal into the canister, layer separation, drying, rotation evaporator, and micronization. All modules have ANFD and micronizers in SS packing isolators. The QC lab relates to Empower 3 servers and all the data related to in-process, intermediate, and complete analysis steps are transferred to SAP through LIMS software. We also offer special analytical services such as PSD, XRD, and microbiology.
CTO-3 is one of our key sites, intended for all phases of molecules. Apart from the regular chemistry, this site can handle Cryo reactions, Hydrogenations, Suzuki coupling reactions, and many other complex reactions. In addition to the 10-production block, CTO-3 is equipped with a GMP kilo lab which enables quick scale-up to support each phase of development. The facility also comes with state-of-the art QC labs, clean rooms, downstream operations such as filtration, drying, and multi mills. This facility is inspected by all major regulatory agencies such as the FDA, WHO GMP, MHRA, COFEPRIS, and KFDA.
CTO-5 is used typically for tonnage volume CMO projects. This site is equipped with 16 production blocks and 12 clean rooms. There are 150+ reactors of sizes ranging from 3kl to 10 kl and above and downstream unit operations such as filters, dryers, centrifuges, multi-mills, micronizers, and ATFDs operational on the site. This site is inspected by agencies such as the FDA, PMDA, EDQM, COFEPRIS, KFDA, and MHRA.
CTO-6 is one of our key sites operating in the Visakhapatnam cluster. This site manufactures intermediates, non-potent APIs, High Potent APIs (HPAPIs), and peptides. This facility has 12 production blocks and 18 clean rooms. This facility hosts a dedicated high-potent production block, QC, and warehousing. The peptide block is equipped with a PB-16 synthesizer and associated downstream equipment such as rotavapours, ion exchange resins and lyophilization. CTO 6 is audited by the US FDA, WHO GMP, PMDA, EMA, Health Canada, CFDA, COFEPRIS, and MHRA.
CTO-SEZ is one of our most modern automated facilities where we manufacture Intermediates, non-potent APIs, High Potent APIs (HPAPIs), and peptides. This facility is equipped with a 100L capacity peptide synthesizer and associated downstream equipment like rotavapor, and ion exchange resins. The high potent block holds 7 reactors from 160L to 1 KL capacity ranges. The facility also can handle various unit operations such as ANFD, ATFD, fluid bed dryer, multi-mill, micronizers, lyophilizers, Tangential flow filtration (TFF). This facility is audited by various agencies such as the USFDA, MFDS, and Russian Federation.
Located in Cuernavaca, Mexico, this facility has over 4 decades of experience in manufacturing steroidal APIs. Our Mexico facility is equipped with dedicated, and physically separated bays as well as dedicated HVAC systems for steroidal as well as non-steroidal API production. Our reaction volume in the steroidal area ranges from 30 to 1000 gallons. This site is audited by various agencies such as the US FDA, COFEPRIS, Russian Federation and KFDA.
Plants across continents (India, UK and Mexico)
20+ years of legacy, 500+ molecules worked on, 15+ commercialized
Global regulatory inspections (such as the US FDA, PMDA, EDQM and MHRA)
cGMP scale from kg to MT
Wide range of technologies & niche reactions (peptide, steroid and high potent)
Wide range of unit operations
MAY 19, 2023
Medicine is an essential part of our life. Since ancient time human civilization has been tirelessly engaged to understand the cause and effect of a disease. Sometimes they win and many times they loss. But the story of their curiosity and enthusiasm is a never damping process. On the contrary it increases day by day, year after year.  ...Read More
APRIL 24, 2023
JUNE 30, 2022
FEBRUARY 23, 2021
Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contract development and manufacturing organizations (CDMOs) for collaborations as they seek more adaptable capacity and c...Read More
Project challenge: Complex carbohydrate chemistry involving a linear sequence of 10 chemical transformations, unstable intermediates and column chromatographic purications. Solution design: Process research and optimization was performed to develop a robust and scalable process which was implemented on commercial scale. Telescoping of reactions reduced the number...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.